TickerTalks
Browse all tickers →
TickerTalks›$HNGE
HNHNGE

Hinge Health, Inc.

$HNGE·$7.4B·Medical - Healthcare Information Services·Healthcare
$97.48+0.3%YTD+109.4%1Y+98.1%
Price updated 2m ago·X counts updated 4d ago
HNHNGE
$HNGEHinge Health, Inc.
$97.49+0.25%59 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $HNGE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

59X posts · last 7 days
Sep 13Sep 27
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $HNGE's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 92% of tracked names.

Mixed sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-15

Hinge Health chartists cite a very tight setup with a Prime Report focus-list mention, but the pre-market gap-up saw only 38K in volume ($4M) — 'volume context of a breakout is very important' captures the wait-and-see tone.

Read what X is saying about $HNGE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $HNGE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-01

The move is getting stronger, with heavier trading behind it.

Digital-MSK care platform doubled off IPO, Q1 revenue +47%, 52-week range position 98% — momentum is real

Hinge Health is a $7.4B digital-musculoskeletal-care platform that doubled off its IPO level, revenue grew 47% in Q1, and the stock sits at the top of its 52-week range just ahead of Nov 3 Q3 earnings.

  • Q1 2026 revenue $182M (+47% year over year), operating margin 17.6%, EPS $0.43; last two earnings surprises -4% and +15% — Q2 just missed consensus slightly, which is the only crack in an otherwise clean growth narrative
  • 2026 analyst consensus is $859M revenue and $2.32 EPS; forward P/E on the $97.24 share price is ~42x — rich on earnings but defensible on the growth cadence and TAM
  • 52-week range position 98%, +11% versus the 50-day, 15 insider events in the recent window — mostly post-IPO lockup sales (President James Pursley sold 33K shares); supply is real into any pullback

The Aug 18 San Francisco office lease (119K square feet at 300 Mission) is a growth-capex commitment — leases that size signal multi-year scale planning.

Agrees with X sentimentX correctly flags a tight chart setup and the Prime Report mention, with a sober observation that the pre-market gap-up came on only 38K shares ($4M notional) — thin volume for a breakout. That matches the data: growth is real, 52-week high is real, but the recent insider selling and the slight Q2 miss both make the breakout a less-clean setup than the chart alone suggests.

What to watch: Nov 3 Q3 earnings — whether revenue growth stays above 40%, operating margin direction, and whether post-IPO insider selling continues to pressure the tape.

On the calendar: 2026-11-03 — Q3 2026 earnings

Read the AI verdict on $HNGE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Digital health company providing a musculoskeletal care platform with exercise therapy, acute injury care, and post-surgical rehabilitation for employers and insurers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $HNGE.

Medical - Healthcare Information Services · Healthcare

No material change from last week — AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers.

What this means for $HNGE

Neutral — Digital health company providing a musculoskeletal care platform with exercise therapy, acute injury care, and post-surgical rehabilitation for employers and insurers.

Industry benchmark

10-name peer basket
+9.0%YTD
+1.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-166%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-81.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
80.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.59$0.61-4.1%
Q1 2026May 5, 2026$0.45$0.39+15.4%
Q4 2025Feb 10, 2026$0.49$0.04+1125.0%
Q3 2025Nov 4, 2025$0.34$0.24+41.7%
Next earningsTue, Nov 3·consensus EPS $0.63

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$182.3M+47.2%84.6%17.6%$0.43$43.0M
Q4 FY25$170.7M+45.6%84.4%16.0%$0.39$63.5M
Q3 FY25$154.2M+53.3%81.9%-4.0%$-0.02$81.3M
Q2 FY25$139.1M+54.9%70.3%-417%$-7.38$18.4M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$859.3M$808.5M – $881.8M$2.32$2.18 – $2.6212
FY27$1.1B$980.4M – $1.2B$2.93$2.62 – $3.3212
FY28$1.3B$1.3B – $1.5B$4.45$3.04 – $5.689
FY29$1.7B$1.6B – $1.8B$4.36$4.09 – $4.734
FY30$2.0B$1.9B – $2.1B$5.29$4.96 – $5.744

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.98%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+60.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 73.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.365-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 21James PursleyPresident33.0K sh$3.1MSellSep 14Elliott RobinsonDirector— sh—SellSep 14Mecklenburg Gabriel M.i.Chair150.0K sh$14.0MSellSep 11Mecklenburg Gabriel M.i.Chair250.0K sh$22.2MSellSep 10Perez Daniel AntonioCEO250.0K sh$22.4MSellSep 10James BudgeCFO55.6K sh$5.0MSellSep 9Elliott RobinsonDirector— sh—SellSep 8Elliott RobinsonDirector— sh—SellSep 3Elliott RobinsonDirector— sh—SellAug 26Elliott RobinsonDirector— sh—
1–10 of 19
+ 27 other (11 conversions · 8 inkinds · 3 awards · 2 gifts · 2 exempts · 1 other) in window

See when $HNGE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementAug 218-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Hinge Health (HNGE) entered into an office lease on August 18, 2026 with 50 Beale Street LLC for approximately 119,278 rentable square feet at 300 Mission Street, San Francisco, CA; the lease commences five business days after tenant improvement completion. Item 2.03 indicates a financial obligation was created; specific rent, lease term, and total obligation are not visible in the excerpt. A 119,000+ sq ft San Francisco office commitment is a significant real estate liability for Hinge Health; the post-IPO expansion signals investment in headcount growth despite high Bay Area costs.

8-KPress release / Reg FDAug 48-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Hinge Health, Inc. filed its Q2 2026 earnings 8-K on August 4, 2026, reporting financial results for the second quarter ended June 30, 2026 via a press release (Exhibit 99.1). Hinge Health is a digital musculoskeletal care platform delivering virtual physical therapy to employer and health plan clients, recently listed on NYSE as an emerging growth company. Items 7.01 and 8.01 suggest supplemental materials were also disclosed alongside the quarterly results. This is a routine but closely watched quarterly earnings disclosure for a high-growth digital health company.

8-KPress release / Reg FDJun 98-K — Item 7.01: Press release / Reg FD
AI summary

Hinge Health, Inc. announced its first Investor Day at Movement on June 9, 2026, and raised guidance for Q2 2026 and full year 2026 via a press release. A guidance raise concurrent with a first Investor Day signals management confidence at this digital physical therapy company. Body unavailable — specific guidance figures are in the attached Exhibit 99.1 press release, not in the excerpt.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Hinge Health, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026; Class A common stockholders had 1 vote per share and Class B stockholders had 15 votes per share under the dual-class structure (giving founders dominant control); two proposals were voted upon. Routine annual meeting; the Class B super-voting structure ensures founders control director elections. Specific vote counts are not detailed in the available excerpt.

8-KPress release / Reg FDMay 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Hinge Health Inc. reported Q1 2026 financial results for the quarter ended March 31, 2026, with a conference call scheduled for May 5, 2026 at 1:30 PM PT / 4:30 PM ET. Non-GAAP financial reconciliations are included in the press release. Hinge Health operates a digital musculoskeletal (MSK) care platform providing therapy, exercise, and education programs for chronic pain conditions. Body unavailable — Q1 2026 financial results are furnished in the attached press release (Exhibit 99.1), not in the 8-K body.

+ 11 other (6 13Gs · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

3 Healthcare Stocks Showing Why the Sector Still Has Momentummarketbeat.com·3d agoHinge Health (NYSE:HNGE) President James Pursley Sells 33,000 Shares of Stockdefenseworld.net·8d agoCritical Comparison: Hinge Health (NYSE:HNGE) & CorVel (NASDAQ:CRVL)defenseworld.net·10d agoReasons to Hold Hinge Health Stock in Your Portfolio for Nowzacks.com·10d agoGabriel M.I. Mecklenburg Sells 150,000 Shares of Hinge Health (NYSE:HNGE) Stockdefenseworld.net·15d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HCAT$DOCS$TDOC$SOPH$BTSG$OPRX$HTFL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport